300204 Staidson
- 6.64
- +0.09+1.37%
Staidson News
Pharmaceutical stocks rose and spread in the afternoon. Various branches such as synthetic biology, peptide drugs, and CRO resonated. Joint Pharmaceutical and Xiangxue Pharmaceutical rose and stopped 20CM, Shutai Shenzhou rose more than 10%, and Tuoxin Ph
Pharmaceutical stocks rose and spread in the afternoon. Various branches such as synthetic biology, peptide drugs, and CRO resonated. Joint Pharmaceutical and Xiangxue Pharmaceutical rose and stopped 20CM, Shutai Shenzhou rose more than 10%, and Tuoxin Pharmaceutical, Yiqiao Shenzhou, and Heyuan Biotech rose more than 10%.
Shu Taishen (300204.SZ): Net loss of 3.7694 million yuan in the first quarter
Gelonghui, April 24 | Shu Taishen (300204.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 94.9834 million yuan, an increase of 46.09% over the previous year; net profit attributable to shareholders of listed companies - 37.694 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 4,4392 million yuan; basic earnings per share - 0.01 yuan.
“Doesn't your heart hurt?” Senior shareholders' souls torture Chairman Shu Taishen, and there is no solution to the slump in stock prices|Direct hit on performance
① At the results meeting, investors were most concerned about the company's losses over the years, high R&D expenses, and tight cash flow; ② Currently, the company is facing various operating difficulties. During this period, the souls of self-proclaimed senior shareholders also tortured the company's chairman Zhou Zhiwen, “Doesn't it hurt?”
Shu Taishen (300204.SZ): The company holds Shu Weixin's production approval. Currently, this product is a reserve project
Gelonghui, April 17 | Shu Taishen (300204.SZ) said at an investor relations event that the company holds Shu Weixin's production approval. Currently, this product is the company's reserve project, and the production plan will be adjusted in due course according to market conditions.
Sultaishen (300204.SZ): STSP-0902 injection for clinical trial application for the treatment of oligospermia was accepted
Shu Taishen (300204.SZ) announced that the company received the “Notice of Acceptance”, an administrative license document from the State Drug Administration, and the State Drug Administration agreed to accept the clinical trial application submitted by Shu Taishen for the treatment of STSP-0902 injection for the treatment of oligospermia.
Shu Taishen: STSP-0902 Eye Drops Application for New Drug Clinical Trials Accepted
Shu Taishen announced that STSP-0902 eye drops were accepted for clinical trial applications for new drugs.
Is the expansion of losses compounded by the cutting of multiple pipelines under development, and Shu Taishen's cash flow problem “always difficult”? |Annual Report Interpretation
① After 3 consecutive years of losses, Shu Taishen's loss margin in 2023 increased further. ② Due to the parallel development of multiple R&D pipelines, R&D expenses continued to rise and surpassed annual revenue for the first time, further tightening the company's cash flow. ③ At the same time, the company announced that it will end a number of R&D projects related to COVID-19 indications.
Shu Taishen (300204.SZ): Plans to absorb and merge wholly-owned subsidiary Defengrui
Gelonghui, March 25 | Shu Taishen (300204.SZ) announced that according to the company's business processing needs, the company plans to carry out an absorption merger with its wholly-owned subsidiary, Beijing Defengrui Biotechnology Co., Ltd. (“Defengrui”). After the merger is completed, Defengrui's independent legal personality will be cancelled, and all of its assets, debts, and all other rights and obligations will be inherited by the company according to law. After the merger was completed, the company's registered capital and business scope remained unchanged, while the shareholding structure and composition of the board of directors, supervisors, and senior management personnel did not change as a result of the merger.
Shu Taishen (300204.SZ): 2023 net loss of 399 million yuan
On March 25, Ge Longhui | Shu Taishen (300204.SZ) announced the 2023 annual report. During the reporting period, the company achieved operating income of 364 million yuan, a year-on-year decrease of 33.66%; operating profit - 366 million yuan, net profit attributable to shareholders of listed companies - 399 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 406 million yuan; and basic earnings per share.
Express News | Shu Taishen: Terminating clinical trials for some ongoing research projects
Express News | Shu Taishen: BDB-001 injection (indications for moderate to severe suppurative hidradenitis) obtained phase I II clinical study summary report
The actual controller of Shu Taishen (300204.SZ) received a warning letter from the Beijing Securities Regulatory Bureau
Shu Taishen (300204.SZ) announced that the actual controller of the company received supervision from the China Securities Regulatory Commission in Beijing...
Express News | Sultaishen: STSA-1002 injection and STSA-1005 injection were used in combination to obtain a Phase I clinical study summary report
Shu Taishen (300204.SZ): Expected net loss of 344 million yuan to 420 million yuan in 2023
Gelonghui, January 29丨Shu Taishen (300204.SZ) announced that it is expected to have a net loss of 420.6026 million yuan to 344.1294 million yuan in 2023, after deducting non-net loss of 429.0679 million yuan to 35,10555 million yuan, and operating income of 32,779.43 million yuan to 40,06.375 million yuan. During the reporting period, the company's production and operation activities were normal. The company actively carried out various marketing and market exploration work, and focused on expanding the layout of new products. Affected by factors such as the external environment and industry policies, the company's main business revenue declined during the reporting period; the company base
Shu Taishen (300204.SZ): The Shenzhen Stock Exchange terminated the review of the company's fixed stock increase
Zhitong Finance App News, Shu Taishen (300204.SZ) announced that on January 10, 2024, the company and sponsor Guojin Securities Co., Ltd. submitted the “Application of Shu Taishen (Beijing) Biopharmaceutical Co., Ltd. to withdraw the 2022 application documents for issuing shares to specific targets and listing on GEM” and “Guojin Securities Co., Ltd.'s application to withdraw the application documents for the 2022 issuance of shares to specific targets and listing on GEM” to the Shenzhen Stock Exchange. The Shenzhen Stock Exchange decided to terminate the company's application to the Special Committee
Shu Taishen (300204.SZ): Termination of issuance of shares to specific targets and withdrawal of application documents
Gelonghui, January 8, 丨 Shu Taishen (300204.SZ) announced that the company held the 22nd meeting of the 5th board of directors and the 22nd meeting of the 5th board of supervisors on January 8, 2024. The meetings separately reviewed and passed the “Proposal on Termination of Issuance of Shares to Specific Targets and Withdrawal of Application Documents”, agreeing that the company will stop issuing shares to specific targets. Since the announcement of the company's 2022 share issuance plan to specific targets, the company and relevant intermediaries have actively promoted related work, and are now comprehensively considering current capital market conditions, policy changes, company development plans and market financing
Sultaishen (300204.SZ): STSA-1001 injection for treating cancer pain obtained a clinical trial notice for a new drug
Gelonghui, January 3 | Shu Taishen (300204.SZ) announced that recently, Shu Taishen (Beijing) Biopharmaceutical Co., Ltd. received the “Drug Clinical Trial Approval Notice” (Notice No.: 2024LP00023) for STSA-1001 injection to treat cancer pain from the State Drug Administration, agreeing to carry out clinical trials on cancer pain with this product. STSA-1001 injection is a recombinant anti-NGF wholly human IgG1 monoclonal antibody injection. The antibody can effectively block the binding of NGF to its receptors, thereby effectively inhibiting NGF signals in pain diseases
Shutaishen (300204.SZ): BDB-001 injection (an indication for ANCA-associated vasculitis) included as a breakthrough treatment variety
Gelonghui, December 19丨Shutaishen (300204.SZ) announced that, according to public information issued by the Drug Evaluation Center of the State Drug Administration (“CDE”), Shutaishen (Beijing) Biopharmaceutical Co., Ltd. and its wholly-owned subsidiary Beijing Defengrui Biotechnology Co., Ltd. (“Defengrui”) applied for a breakthrough treatment in the BDB-001 injection project for anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV) recently completed a public announcement and has been included in the list of breakthrough treatment varieties.
Shu Taishen (300204.SZ): Xiangtang Group plans to reduce its shares by no more than 1%
On December 15, Gelonghui (300204.SZ) announced that Xiangtang Group Co., Ltd., a shareholder holding 5% or more of Shu Taishen shares (8.68% of the company's total share capital), plans to reduce its holdings of the company's shares by no more than 4.7777 million shares (about 1% of the company's total share capital) through centralized bidding within 3 months of 15 trading days from the date of disclosure of the announcement.
Express News | Twenty listed companies, including Hengrui Pharmaceutical and China Resources Shuanghe, announced after the market that drugs entered the national health insurance catalogue, Junshi Biotech and Zhongsheng Pharmaceutical's COVID-19 drugs were included
Analysis
Price Target
No Data
